請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50297
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Jiuan Shen),王繼娟(Chi-Chuan Wang) | |
dc.contributor.author | Hsien-Tsung Chiu | en |
dc.contributor.author | 邱賢宗 | zh_TW |
dc.date.accessioned | 2021-06-15T12:35:26Z | - |
dc.date.available | 2021-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-01 | |
dc.identifier.citation | 1. 認識流感疫苗-教學手冊. (Accessed May 25, 2016, at http://www.cdc.gov.tw/professional/page.aspx?treeid=beac9c103df952c4&nowtreeid=45e72c18c1ff4691.)
2. Control CfD, Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Early release 2009;58:1-54. 3. 歷年接種資料. (Accessed May 25, 2016, at http://www.cdc.gov.tw/professional/list.aspx?treeid=8208eb95dda7842a&nowtreeid=A4C431743AAA081F.) 4. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-6. 5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014;63:2889-934. 6. Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. Jama 2014;311:463-4. 7. Liao JK, Laufs U. Pleiotropic effects of statins. Annual review of pharmacology and toxicology 2005;45:89-118. 8. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature reviews Drug discovery 2005;4:977-87. 9. Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends in cardiovascular medicine 2005;15:202-6. 10. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza Vaccine Response in Elderly Individuals. The Journal of infectious diseases 2015. 11. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. The Journal of infectious diseases 2015. 12. 流感疫苗實施對象. (Accessed May 26, 2016, at http://www.cdc.gov.tw/page.aspx?treeid=D78DE698C2E70A89&nowtreeid=A087915DD66C4894.) 13. Quandelacy TM, Viboud C, Charu V, Lipsitch M, Goldstein E. Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997-2007. Am J Epidemiol 2014;179:156-67. 14. Meerhoff TJ, Simaku A, Ulqinaku D, et al. Surveillance for severe acute respiratory infections (SARI) in hospitals in the WHO European region - an exploratory analysis of risk factors for a severe outcome in influenza-positive SARI cases. BMC infectious diseases 2015;15:1. 15. Punpanich W, Chotpitayasunondh T. A review on the clinical spectrum and natural history of human influenza. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2012;16:e714-23. 16. Brydak LB, Machala M. Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 2000;60:35-53. 17. Hsieh Y-C, Chen H-Y, Yen J-J, et al. Influenza in Taiwan: seasonality and vaccine strain match. Journal of microbiology, immunology, and infection= Wei mian yu gan ran za zhi 2005;38:238-43. 18. Haanen JB, Wolkers MC, Kruisbeek AM, Schumacher TN. Selective expansion of cross-reactive CD8(+) memory T cells by viral variants. The Journal of experimental medicine 1999;190:1319-28. 19. Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC medicine 2013;11:153. 20. Castilla J, Martinez-Baz I, Martinez-Artola V, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2013;18. 21. Simpson CR, Lone N, Kavanagh K, et al. Health Services and Delivery Research. Seasonal Influenza Vaccine Effectiveness (SIVE): an observational retrospective cohort study - exploitation of a unique community-based national-linked database to determine the effectiveness of the seasonal trivalent influenza vaccine. Southampton (UK): NIHR Journals Library Copyright (c) Queen's Printer and Controller of HMSO 2013. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.; 2013. 22. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-69. 23. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005;23 Suppl 1:S10-25. 24. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Current opinion in immunology 2009;21:418-24. 25. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert review of vaccines 2012;11:985-94. 26. Fu C, Xu J, Lin J, et al. Concurrent and cross-season protection of inactivated influenza vaccine against A(H1N1)pdm09 illness among young children: 2012-2013 case-control evaluation of influenza vaccine effectiveness. Vaccine 2015;33:2917-21. 27. Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. The Journal of infectious diseases 2014;210:126-37. 28. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014;59:1375-85. 29. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014;58:319-27. 30. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012–2013 season: assessments of prior vaccination and serologic susceptibility. Journal of Infectious Diseases 2015;211:1519-28. 31. Castilla J, Navascues A, Fernandez-Alonso M, et al. Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons. Vaccine 2016;34:1350-7. 32. Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. The British journal of general practice : the journal of the Royal College of General Practitioners 2011;61:e742-8. 33. Nielsen AG, Nielsen RB, Riis AH, Johnsen SP, Sorensen HT, Thomsen RW. The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Critical care 2012;16:R122. 34. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. The Journal of infectious diseases 2012;205:13-9. 35. Brett SJ, Myles P, Lim WS, et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PloS one 2011;6:e18120. 36. Viasus D, Pano-Pardo JR, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. The Journal of infection 2011;62:193-9. 37. Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Critical care medicine 2011;39:1871-8. 38. Magulick JP, Frei CR, Ali SK, et al. The effect of statin therapy on the incidence of infections: a retrospective cohort analysis. The American journal of the medical sciences 2014;347:211-6. 39. Laidler MR, Thomas A, Baumbach J, et al. Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations. Open forum infectious diseases 2015;2:ofv028. 40. Lee PY, Scumpia PO, Byars JA, et al. Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers. Vaccine 2006;24:4035-40. 41. Packard RR, Schlegel S, Senouf D, et al. Atorvastatin treatment and vaccination efficacy. Journal of clinical pharmacology 2007;47:1022-7. 42. Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clinical immunology 2006;119:1-12. 43. Ghittoni R, Patrussi L, Pirozzi K, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19:605-7. 44. Saoudi A, Kassem S, Dejean A, Gaud G. Rho-GTPases as key regulators of T lymphocyte biology. Small GTPases 2014;5. 45. Mondino A, Khoruts A, Jenkins MK. The anatomy of T-cell activation and tolerance. Proceedings of the National Academy of Sciences of the United States of America 1996;93:2245-52. 46. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nature medicine 2000;6:1399-402. 47. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss medical weekly 2001;131:41-6. 48. Ghittoni R, Napolitani G, Benati D, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. European journal of immunology 2006;36:2885-93. 49. Fehr T, Kahlert C, Fierz W, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004;175:83-90. 50. Anderson ME, Siahaan TJ. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 2003;24:487-501. 51. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989;341:619-24. 52. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. Journal of molecular biology 1999;292:1-9. 53. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature medicine 2001;7:687-92. 54. Wagner AH. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase-Independent Inhibition of CD40 Expression by Atorvastatin in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2002;22:1784-9. 55. Mulhaupt F. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovascular Research 2003;59:755-66. 56. 疾病分類代碼及範圍. (Accessed May 25, 2016, at http://www.nhi.gov.tw/webdata/webdata.aspx?menu=18&menu_id=703&webdata_id=1008.) 57. 健保用藥品項104年11月壓縮總檔. (Accessed May 26, 2016, at http://www.nhi.gov.tw/webdata/webdata.aspx?menu=8&menu_id-498&WE_ID=498&webdata_id=873.) 58. WHO recommendations on the composition of influenza virus vaccines. (Accessed May 25, 2016, at http://www.who.int/influenza/vaccines/virus/recommendations/en/.) 59. 流感速訊. (Accessed May 25, 2016, at http://www.cdc.gov.tw/submenu.aspx?treeid=1F07E8862BA550CF&nowtreeid=BCC260C5073450D7.) 60. 傳染病統計暨監視年報. (Accessed June 29, 2016, at http://www.cdc.gov.tw/professional/infectionreport.aspx?treeid=56ca56252a0fa705&nowtreeid=ca20fc0dab36f820.) 61. Key Facts About Seasonal Flu Vaccine. (Accessed June 17, 2016, at http://www.cdc.gov/flu/protect/keyfacts.htm.) 62. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care 2005:1130-9. 63. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54. 64. Chang HY, Bodycombe DP, Huang WF, Weiner JP. Risk-adjusted resource allocation: using Taiwan's National Health Insurance as an example. Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for Public Health 2015;27:NP958-71. 65. Rubin DB. Estimating causal effects from large data sets using propensity scores. Annals of internal medicine 1997;127:757-63. 66. Hosmer DW, Lemeshow S. Introduction to the logistic regression model. Applied Logistic Regression, Second Edition 2000:1-30. 67. Fraeman KH, Evidera B. A General SAS® Macro to Implement Optimal N: 1 Propensity Score Matching Within a Maximum Radius. 68. Matching SAS code. (Accessed May 25, 2016, at http://blog.yam.com/imaltar/article/29382290.) 69. Institute S. SAS Institute version 9.4. Cary NC; 2013. 70. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Communications in Statistics - Simulation and Computation 2009;38:1228-34. 71. Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS®. SAS Global Forum; 2012. 72. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate behavioral research 2011;46:399-424. 73. Normand S-LT, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. Journal of clinical epidemiology 2001;54:387-98. 74. 內政部統計處我國生命表. (Accessed June 22, 2016, at http://www.moi.gov.tw/stat/life.aspx.) 75. 全民健康保險藥物給付項目及支付標準之藥品給付規定. (Accessed May 25, 2016, at http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&webdata_id=2919.) 76. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. Jama 2004;292:1333-40. 77. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama 2003;289:179-86. 78. Seo SH, Webby R, Webster RG. No apoptotic deaths and different levels of inductions of inflammatory cytokines in alveolar macrophages infected with influenza viruses. Virology 2004;329:270-9. 79. McElhaney JE. Influenza vaccine responses in older adults. Ageing research reviews 2011;10:379-88. 80. McElhaney JE, Xie D, Hager WD, et al. T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly. The Journal of Immunology 2006;176:6333-9. 81. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001;154:155-60. 82. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Annals of internal medicine 1995;123:518-27. 83. Bessler H, Salman H, Bergman M, Straussberg R, Djaldetti M. In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clinical immunology 2005;117:73-7. 84. Jameel A, Ooi KG, Jeffs NR, Galatowicz G, Lightman SL, Calder VL. Statin Modulation of Human T-Cell Proliferation, IL-1beta and IL-17 Production, and IFN-gamma T Cell Expression: Synergy with Conventional Immunosuppressive Agents. International journal of inflammation 2013;2013:434586. 85. National Health Insurance Research Database, Taiwan. (Accessed May 25, 2016, at http://nhird.nhri.org.tw/brief_01.html.) 86. Williams CJ, Schweiger B, Diner G, et al. Seasonal influenza risk in hospital healthcare workers is more strongly associated with household than occupational exposures: results from a prospective cohort study in Berlin, Germany, 2006/07. BMC infectious diseases 2010;10:8. 87. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral research 2013;99:417-35. 88. 104年度肺炎鏈球菌多醣體疫苗接種計畫書. (Accessed June 24, 2016, at http://www.cdc.gov.tw/page.aspx?treeid=d78de698c2e70a89&nowtreeid=fba47617d573f4fa.) 89. Chang YC, Chou YJ, Liu JY, Yeh TF, Huang N. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan--a representative population-based comparative study. The Journal of infection 2012;65:231-8. 90. 疾病管制署配合衛生福利部疾病管制署辦理流感疫苗接種計畫藥品品項表. (Accessed June 24, 2016, at http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&webdata_id=873.) | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50297 | - |
dc.description.abstract | 研究背景 Statins的免疫抑制作用可能降低施打疫苗所引起的免疫反應,且可依是否與statins抑制HMG-CoA reductase相關分成數個機轉,如抑制GTPases protein isoprenylation、負調控major histocompatibility complex (MHC)分子的表現等。其中,對於抑制T細胞上的lymphocyte function-associated antigen-1 (LFA-1)與其抑制HMG-CoA reductase無關,且不同statins因結構不同而抑制效果有所差異。不過目前仍尚未有文獻考量不同statins對免疫系統作用的差異,且探討老年族群statins的使用對季節性流感疫苗降低需就醫急性呼吸道疾病效果的影響。
研究目的 利用全民健康保險研究資料庫探討老年族群statins的使用是否會對季節性流感疫苗在需就醫急性呼吸道疾病的發生風險造成影響,並希望進一步探討statins的使用時間點、強度、種類是否與此相關。 研究材料與方法 本研究為回溯性世代研究,以2007-2013年全民健康保險資料庫老人檔為資料來源,疫苗相符或不相符年度各包含3個年度,將各年度10月1日至次年5月31日施打季節性流感疫苗的日期作為index date,以index date前後14天為暴露期間,若暴露期間有使用任何一劑statins則視為有statins的使用,比較兩組在觀察期間發生需就醫急性呼吸道疾病的風險是否有差異。資料分析利用propensity score配對平衡兩組間的基本特性,並以conditional logistic regression進行勝算比(OR)的預測。 研究結果 本研究總樣本數為440,180,2007-2008至2012-2013的6個年度依序分析76,330人、85,545人、34,725人、74,680人、82,560人及86,340人。結果顯示6個年度合併後,老年族群statins的使用會使觀察期間發生需就醫急性呼吸道疾病的風險上升1.03倍(95% CI: 1.02-1.05),在疫苗相符年度或不相符年度結果一致。在次族群分析中,依statins使用時間點分組,僅有疫苗相符年度在施打季節性流感疫苗之後使用statins會使發生需就醫急性呼吸道疾病的風險上升1.06倍(95% CI: 1.02-1.09),而疫苗不相符年度則沒有影響。所有statins中,僅有simvastatin及lovastatin會使發生需就醫急性呼吸道疾病的風險上升,分別為1.14倍(95% CI: 1.10-1.18)及1.18倍(95% CI: 1.12-1.25)。不同年齡層或降血脂強度則未有一致性的趨勢。 結論 本研究發現無論是在疫苗相符或不相符年度,老年族群statins的使用都會降低季節性流感疫苗的效果而使發生需就醫急性呼吸道疾病的風險上升3%,尤其是在疫苗相符年度施打疫苗之後使用statins,所有statins中,simvastatin及lovastatin最有可能影響到季節性流感疫苗的效果,影響程度高達14%及18%。建議臨床上仍應考量使用statins的利益及風險,若為了避免此影響,可選擇pravastatin或不含hexahydronaphthalene的statins,如atorvastatin、fluvastatin或rosuvastatin,或在施打流感疫苗後短暫停用statins數天,而未來也需要更進一步的研究,了解不同statins對免疫系統作用的差異或採用經實驗室確認的流感作為結果。 | zh_TW |
dc.description.abstract | Background: The immunomodulatory effects of statins may reduce the immune response induced by vaccines, which could be divided into several mechanisms depends on the inhibition of HMG-CoA reductase, such as GTPases protein isoprenylation inhibition, down-regulation of major histocompatibility complex (MHC) molecules expression. For the inhibition of lymphocyte function-associated antigen-1 (LFA-1), different statins do not have equal inhibitory effects because of the structural differences and the effects are independent of HMG-CoA reductase. However, there is lack of studies considering the immunomodulatory effects of different statins and focusing on the influence of statins use on the effectiveness of seasonal influenza vaccine against medically attended acute respiratory illness (MAARI) in the elderly.
Objective: To investigate whether statins use influenced the effectiveness of seasonal influenza vaccine on the incidence of MAARI in the elderly and timing of statins exposure, and different potency or types of statins by using the National Health Insurance Research Database in Taiwan. Materials and Methods: We conducted a retrospective cohort study by using the 2007-2013 elderly database from Taiwan’s National Health Insurance Research Database. Vaccine match years and vaccine mismatch years each contained three years. All elderly who were vaccinated with seasonal influenza vaccine during October 1 to May 31 in the next year were enrolled for analysis, and the date of vaccination was defined as index date. People who had any statin use in the exposure period defined as before and after 14 days of index date were statin users, others were statin non-users. We compared the risk of MAARI in the observational period between statin users and statins non-users. Propensity score matching was used to make the two groups comparable. Conditional logistic regression models were used to estimate odds ratios. Results: After matching, total sample size was 440,180. There were 76,330, 85,545, 34,725, 74,680, 82,560 and 86,340 people being analyzed during 2007-2008 to 2012-2013 influenza seasons. In general, the risk of MAARI in the observational period was higher in the elderly who used statins in the exposure period in six years combined data (OR: 1.03, 95% CI: 1.02-1.05). Vaccine match years and vaccine mismatch years both had similar results. In the subgroup analysis, statins use after vaccination in the vaccine match years was associated with higher risk of MAARI in the observational period (OR: 1.06, 95% CI: 1.02-1.09) rather than in the vaccine mismatch years. Among all statins, only simvastatin and lovastatin use in the exposure period had higher risk of MAARI (OR: 1.14, 95% CI: 1.10-1.18; OR: 1.18, 95% CI: 1.12-1.25). No consistent relationships were found in different age groups or lipid-lowering potency groups. Conclusions: Statins use was associated with the 3% reduced effectiveness of seasonal influenza vaccine against MAARI in the elderly, especially statins use after vaccination in the vaccine match years. Simvastatin and lovastatin had 14%-18% higher risk to reduce the effectiveness of seasonal influenza vaccine. We recommended choosing pravastatin or other statins not containing hexahydronaphthalene, such as atorvastatin, fluvastatin, rosuvastatin, or stopping taking statins after vaccination for several days after evaluating the benefit and risk in clinical. In the future, other studies exploring the differences of the statins on the immunomodulatory effects or using the laboratory-confirmed influenza as outcome are needed. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:35:26Z (GMT). No. of bitstreams: 1 ntu-105-R04451001-1.pdf: 1426575 bytes, checksum: 5bff0c22992d5d232a7c7ca28ede565f (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract iv 目錄 vi 表目錄 ix 圖目錄 xii 縮寫表 xiii 第一章 前言 1 第二章 文獻回顧 2 2.1 影響流感疫苗效果的干擾因子 2 2.2 Statins對疫苗效果影響的文獻回顧 5 2.3 Statins對免疫系統作用的研究 6 2.3.1 抑制GTPases protein isoprenylation 6 2.3.2 抑制MHC molecules的表現 7 2.3.3 抑制APCs與T cells之間的co-stimulatory signal 7 2.3.4 Statins影響流感疫苗效果的可能機轉 8 第三章 研究目的 10 3.1 研究動機 10 3.2 研究目的 10 第四章 研究方法 11 4.1 研究設計 11 4.2 資料來源 11 4.3 研究對象 12 4.3.1 研究對象定義 12 4.3.2 篩選研究對象流程 12 4.4 研究期間 12 4.5 定義statins暴露 13 4.5.1 定義每張處方箋的使用期間 13 4.5.2 定義statins暴露資料 13 4.6 定義變項 14 4.6.1 依變項 14 4.6.2 自變項 14 4.6.3 控制變項 14 4.7 Propensity score配對 15 4.8 統計分析 16 4.8.1 作業軟體 16 4.8.2 統計模型設定 16 4.8.3 描述性分析 16 4.8.4 相關性分析 17 4.9 敏感性分析 17 第五章 研究結果 18 5.1 研究族群背景資料 18 5.1.1 納入人數 18 5.1.2 研究族群基本特性 18 5.2 Statins使用與MAARI風險 19 5.3 不同年齡層的statins使用與MAARI風險 20 5.4 Statins使用時間點與MAARI風險 20 5.5 Statins使用強度與MAARI風險 21 5.6 Statins使用種類與MAARI風險 21 5.7 敏感性分析 22 第六章 討論 24 6.1 研究族群基本特性 24 6.2 Statins使用與MAARI風險 24 6.3 不同年齡層的statins使用與MAARI風險 27 6.4 Statins使用時間點與MAARI風險 27 6.5 Statins使用強度或種類與MAARI風險 28 6.6 研究特色與限制 30 6.6.1 研究特色與優點 30 6.6.2 研究限制 31 第七章 結論與建議 33 表 34 圖 78 參考資料 88 | |
dc.language.iso | zh-TW | |
dc.title | 老年族群使用statins對季節性流感疫苗降低需就醫急性呼吸道疾病效果的影響 | zh_TW |
dc.title | Influence of statins use on the effectiveness of seasonal influenza vaccine against medically attended acute respiratory illness in elderly | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳宜君(Yee-Chun Chen),林榮信(Jung-Hsin Lin) | |
dc.subject.keyword | 季節性流感疫苗,需就醫急性呼吸道疾病,statin,老年族群,全民健保資料庫, | zh_TW |
dc.subject.keyword | seasonal influenza vaccine,medically attended acute respiratory illness (MAARI),statin,elderly,National Health Insurance Research Database (NHIRD), | en |
dc.relation.page | 94 | |
dc.identifier.doi | 10.6342/NTU201601653 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-01 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.39 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。